Last $30.37 USD
Change Today 0.00 / 0.00%
Volume 119.1K
EBS On Other Exchanges
New York
As of 8:04 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (EBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/15 - $30.74
52 Week Low
10/15/14 - $19.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

emergent biosolutions inc (EBS) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (EBS) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,353 Employees
Last Reported Date: 03/10/14
Founded in 1998

emergent biosolutions inc (EBS) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.0M
Founder, Executive Chairman and Chairman of S...
Total Annual Compensation: $726.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $694.2K
Executive Vice President and President of Bio...
Total Annual Compensation: $474.8K
Executive Vice President and President of Bio...
Total Annual Compensation: $138.9K
Compensation as of Fiscal Year 2013.

emergent biosolutions inc (EBS) Key Developments

Emergent BioSolutions Plans to Expand in Baltimore

Emergent BioSolutions announced that it plans to break ground on an expansion at one of its two Baltimore locations in the next six months. The addition, expected to cost more than $60 million, would roughly double the company's current space on Lombard Street, where it purchased a 58,000-square-foot multi-use manufacturing building in 2009. The company expects to add about 158 jobs at the site over the next four years.

Emergent BioSolutions, Inc. Appoints Jerome Hauer as Class III Director

On January 22, 2015, the Board of Directors of Emergent BioSolutions Inc. approved an increase in the size of the Board from 9 to 10 directors and appointed Jerome Hauer as a Class III director of the company, with an initial term expiring at the 2015 annual meeting of stockholders.

Emergent BioSolutions, Inc.v Provides Earnings Guidance for the Year 2014; Provides Earnings Guidance for the First Quarter and Full Year of 2015

Emergent BioSolutions, Inc. provided earnings guidance for the year 2014. Net income on an adjusted basis is expected to range $53 million to $55 million, or $1.42 to $1.47 per basic share, on total revenues of $445 million to $450 million. The firm estimates it will have approximately $280 million in cash and cash equivalents at year-end 2014. The company is aiming for first quarter of 2015 non-GAAP adjusted net income of $60 million to $70 million on total revenues of $90 million to $105 million. For 2015, the company is targeting revenue in the range of $510 to $540 million. Adjusted net income is seen at $60 million to $70 million. GAAP net income expected to be in the range of $50 million to $60 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $30.37 USD 0.00

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $16.17 USD -0.01
Bavarian Nordic A/S kr211.00 DKK +1.50
Depomed Inc $22.60 USD +0.08
Nektar Therapeutics $12.98 USD -0.24
Skyepharma PLC 303.00 GBp +2.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EBS Industry Range
Price/Earnings 52.5x
Price/Sales 2.8x
Price/Book 2.2x
Price/Cash Flow 52.2x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at